Business Wire

CLARIUS-MOBILE-HEALTH

17.1.2024 10:01:26 CET | Business Wire | Press release

Share
Clarius Receives CE Mark Certification for its Dual-Array Wireless Handheld Scanner for Whole-Body Ultrasound Imaging

Clarius Mobile Health, a global leader in wireless ultrasound solutions, has received CE Mark for its revolutionary Clarius PAL HD3 wireless handheld whole-body ultrasound scanner combining phased and linear arrays on a single head. It offers superior image quality of superficial and deep anatomy at the bedside1. The Clarius PAL HD3 high-definition wireless scanner is available today in Europe and the United Kingdom.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240117813694/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

New Clarius PAL HD3 wireless handheld whole-body ultrasound scanner uniquely combines phased and linear arrays on a single head. It offers superior image quality of superficial and deep anatomy at the bedside. CE-Certified, it's now available in Europe, the United Kingdom and the United States. (Graphic: Business Wire)

“You can probably do 95 to 99% of all the ultrasound imaging you need to do during a shift with this single device,” says Dr. Tom Cook who practices at a busy urban hospital. “If you compare the cost of this device to a cart-based system, you're talking a factor of 10 to 15, maybe even 20, depending on the type of system you're using. So, it's very, very inexpensive.”

Clarius is as compact as an iPhone and works seamlessly with iOS or Android devices, ensuring easy mobility from patient to patient. Clarius PAL HD3 is the only whole-body handheld scanner to deliver high-resolution images from the skin down to 40 cm of depth. Healthcare professionals can perform whole-body ultrasound exams without the need to swap devices or transport bulky systems between rooms. Clarius PAL HD3 is the 11th wireless handheld ultrasound scanner in the Clarius specialty ultrasound lineup.

“Our unique dual-array design was driven by our objective to deliver a portable whole-body ultrasound device that produces superior imaging quality, performance, and usability than what was currently available for clinicians,” says Kris Dickie, Chief Technology Officer at Clarius who led the project from ideation to commercialization. “Given the sales volume of the Clarius PAL since we introduced it in the United States late last year, we’re happy to confirm there’s definitely a strong market for a single, versatile device that supports multiple exams and broad clinical applications for hospital physicians.”

Clarius ultrasound scanners are proven to deliver superior image quality.1 Clarius uses the same advanced 8 beamformer processing technology used by higher-end traditional systems. This delivers up to 8 times the speed and performance of other handhelds for clear and detailed imaging to guide safe procedures and support precise and rapid assessments of patients at the bedside.

Watch this video to learn more about Clarius PAL HD3 from three emergency physicians.

1. Park KE, Mehta P, Tran C, Parikh AO, Zhou Q, Zhang-Nunes S. A comparison of five point-of-care ultrasound devices for use in ophthalmology and facial aesthetics. Ultrasound. 2023;0(0). doi:10.1177/1742271X231166895

About Clarius Mobile Health
Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty. With decades of experience in medical imaging, the team knows that great ultrasound imaging improves confidence and patient care. Clarius handheld wireless ultrasound scanners connect to iOS and Android devices, delivering high-resolution ultrasound images traditionally only available with bulkier, high-end systems at a fraction of the cost.

Over four million high-definition scans have been performed using Clarius wireless handheld scanners. Clarius scanners are available in over 90 countries worldwide. Learn more at www.clarius.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240117813694/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye